Skip to main content
Smart Investors Daily
EM

NYSE · EMBC

Embecta Corp.

Healthcare · Drug Manufacturers - Specialty & Generic

$6.56

Down-$0.31 (-4.73%)

Updated Oct 31, 2026, 12:40 AM

SID Score

5.4/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
699.2M
P/E ratio
7.38
Dividend yield
9.15%
52-week range
$2.77 – $14.91
Volume
1.11M
Avg. volume
483.6K

Price performance · EMBC

EMBC price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 29, 2026

EMBC closed at $6.56 after 20 trading sessions, up 16.11% for the selected period.

Last close
$6.56
Period change
+16.11%
Period low
$5.65
Period high
$6.86
Daily close
View OHLC price history
EMBC OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 29, 2026$6.52$6.695$6.45$6.561.11M
Oct 28, 2026$6.54$6.60$6.3706$6.46985K
Oct 27, 2026$6.80$6.895$6.49$6.551.28M
Oct 26, 2026$6.70$6.83$6.6499$6.80679.49K
Oct 23, 2026$6.77$6.88$6.69$6.71717.02K
Oct 22, 2026$6.64$6.90$6.625$6.86922.04K
Oct 21, 2026$6.37$6.735$6.35$6.68706.69K
Oct 20, 2026$6.29$6.515$6.205$6.42746.14K
Oct 19, 2026$6.395$6.395$6.20$6.21899.66K
Oct 16, 2026$6.51$6.53$6.26$6.27622.68K
Oct 15, 2026$6.19$6.58$6.19$6.45983.71K
Oct 14, 2026$6.19$6.25$6.11$6.18651.48K
Oct 13, 2026$6.01$6.24$5.925$6.20732.77K
Oct 12, 2026$5.77$6.11$5.77$5.991.05M
Oct 9, 2026$5.74$5.95$5.67$5.685583.11K
Oct 8, 2026$5.89$5.9749$5.725$5.751.14M
Oct 7, 2026$5.86$6.16$5.86$5.91994.13K
Oct 6, 2026$5.90$6.145$5.80$5.951.21M
Oct 5, 2026$5.59$5.97$5.565$5.881.04M
Oct 2, 2026$5.79$5.82$5.49$5.651.14M

Latest EMBC news

The latest Smart Investors Daily articles mentioning EMBC.

EMBC research

Overview

Company profile and research snapshot.

Company profile

Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Hold
Average target
$22.50
Implied upside
—
Analysts
9
EMBC recent ratings
DateFirmRatingTarget
May 18, 2026B of A SecuritiesUnderperform—
May 6, 2026MizuhoNeutral—
May 6, 2026BTIGNeutral—
Apr 13, 2026MizuhoNeutral—
Feb 6, 2026BTIGBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 20, 2026

What Embecta Bears Saw Before A 55% Drop

If you had backed Embecta on 19 October 2025 and simply held on, the experience would have been brutal. Holding Embecta over the past year would have meant a 54.5% loss, including dividends. At the start, bullish and bearish analysts were arguing over modest revenue shrinkage, margin expansion into the mid teens, and a future P/E between 7.4x and 4.7x. So what did that original investment case miss about pen needle reliance, GLP-1 partnerships and margin durability? The move put Embecta in...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.